Angiogenic and Antiangiogenic Markers for Prediction and Risk Classification of Preeclampsia

Clinical Obstetrics and Gynecology

Volumn 60, Issue 1, 2017, Pages 134-140

  Malshe, Amol K ^a   Sibai, Baha M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

PlGF; preeclampsia angiogenic factors; sFlt1

Indexed keywords

ANGIOGENIC FACTOR; BIOCHEMICAL MARKER; FMS LIKE PROTEIN KINASE 1; PLACENTAL GROWTH FACTOR; PROTEIN KINASE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; MORBIDITY; MORTALITY; PREDICTION; PREECLAMPSIA; RISK; BLOOD; FEMALE; HUMAN; PREGNANCY; PREGNANCY COMPLICATION;

ANGIOGENESIS INHIBITORS; BIOMARKERS; FEMALE; HUMANS; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 85008422981     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000267     Document Type: Article

References (38)

1. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122-1131.
2. Saleem S, McClure EM, Goudar SS, et al. A prospective study of maternal, fetal and neonatal deaths in low-and middle-income countries. Bull World Health Organ. 2014;92:605-612.
3. Karumanchi SA. Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension. 2016;67:1072-1079.
4. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet. 2005;365:785-799.
5. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:181-192.
6. Lever J. Cases of puerperal convulsions with remarks. Guys Hosp Rep. 1843;2:495-517.
7. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103(pt 1):981-991.
8. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994;309:1395-1400.
9. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014;63:198-202.
10. Fisher KA, Luger A, Spargo BH, et al. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore). 1981;60:267-276.
11. Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33:196-205.
12. Vatish M, Strunz-McKendry T, Hund M, et al. The sflt-1/plgf ratio test in pre-eclampsia: an economic assessment for the UK. Ultrasound Obstet Gynecol. 2016;48:765-771.
13. Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol. 2015;213 (suppl):S115-S122.
14. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
15. Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466-480.
16. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856-2869.
17. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
18. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884-891.
19. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293:77-85.
20. Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122:478-487.
21. Sibai BM. Biomarker for hypertension-preeclampsia: are we close yet? Am J Obstet Gynecol. 2007;197:1-2.
22. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
23. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58 e1-58 e8.
24. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190: 1541-1547; discussion 7-50.
25. Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, et al. Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol. 2014;10:531-540.
26. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374:13-22.
27. McElrath TF, Lim KH, Pare E, et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol. 2012;207:407 e1-407 e7.
28. Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5:e13263.
29. Benzing T. Hypertension: Testing for preeclampsia: paving the way to early diagnosis. Nat Rev Nephrol. 2016;12:200-202.
30. Seely EW, Solomon CG. Improving the Prediction of Preeclampsia. N Engl J Med. 2016;374: 83-84.
31. Khong Y, Brosens I. Defective deep placentation. Best Pract Res Clin Obstet Gynaecol. 2011;25: 301-311.
32. Redman CW, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2015;213 (suppl):S9.e1-S9.e11.
33. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9-23.
34. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911-919.
35. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128: 2121-2131.
36. Andersen LB, Dechend R, Jorgensen JS, et al. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort. Hypertens Pregnancy. 2016;35: 405-419.
37. Duckworth S, Griffin M, Seed PT, et al. Diagnostic Biomarkers in Women With Suspected Preeclampsia in a Prospective Multicenter Study. Obstet Gynecol. 2016;128:245-252.
38. Klein E, Schlembach D, Ramoni A, et al. Influence of the sFlt-1/PlGF ratio on clinical decisionmaking in women with suspected preeclampsia. PLoS One. 2016;11:e0156013.